[Studies on antimicrobial concentration of clindamycin phosphate in serum, pelvic dead space exudate, and pelvic organs/tissues].
In women undergoing radical and total abdominal hysterectomy, clindamycin phosphate (CLDM-P) in a dose of 1,200 mg was administered by intravenous drip infusion over 1 hour and the drug concentrations in serum and pelvic dead space exudate, as well as pelvic organs/tissues, were determined over time. The following results were obtained: The serum concentration of clindamycin (CLDM) after intravenous infusion showed the peak value of 24.54 +/- 7.02 micrograms/ml at the end of infusion and then gradually decreased to 3.87 +/- 0.70 micrograms/ml in 6 hours. Concentration in pelvic dead space exudate, which was 2.82 +/- 3.90 micrograms/ml at the end of intravenous infusion, gradually increased to the peak value of 13.49 +/- 6.62 micrograms/ml in 1 hour. Two hours after infusion, the level of 12.43 +/- 5.56 micrograms/ml outstripped serum concentration. Continuously in excess of serum concentration, the exudate concentration gradually decreased to 6.65 +/- 2.27 micrograms/ml at 6 hours after infusion. Cubital venous serum concentration (16.36 +/- 3.68 micrograms/ml) was almost equal to uterine arterial serum concentration (16.36 +/- 4.05 micrograms/ml) of CLDM at uterine removal. In the pelvic organ/tissue concentrations, 15.71 +/- 3.86 micrograms/g in endometrium was highest, followed by 15.19 +/- 3.80 micrograms/g in oviduct, 14.80 +/- 3.52 micrograms/g in myometrium, 14.74 +/- 4.02 micrograms/g in ovary, 14.09 +/- 2.90 micrograms/g in portio vaginalis. The concentration was lowest (11.49 +/- 1.44 micrograms/g) in cervix uteri. Clinically, combined treatment with CLDM-P and ceftizoxime was excellently effective for endometritis induced by P. asaccharolyticus.(ABSTRACT TRUNCATED AT 250 WORDS)
T
T
Obata
J
J
Sasaki
K
K
Takahashi
M
M
Eguchi
Y
Y
Yamamoto
K
K
Deguchi
S
S
Fukayama
Y
Y
Nishimura
D000328:Adult; D000368:Aged; D002981:Clindamycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy; D005122:Exudates and Transudates / Q000378:metabolism*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D008954:Models, Biological; D010388:Pelvis / Q000378:metabolism*; D014599:Uterus / Q000378:metabolism*
D002981:Clindamycin; C007084:clindamycin phosphate